Zobrazeno 1 - 10
of 198
pro vyhledávání: '"James F. Howard"'
Publikováno v:
Global Epidemiology, Vol 7, Iss , Pp 100145- (2024)
Objective: Claims data can be leveraged to study rare diseases such as Guillain-Barré Syndrome (GBS), a neurological autoimmune condition. It is difficult to accurately measure and distinguish true cases of disease with claims without a validated al
Externí odkaz:
https://doaj.org/article/4abf6e9c9e984cc3a6b4643bd1f4c8c5
Autor:
James F. Howard, Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J. Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Richard J. Nowak, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D. Weiss, Małgorzata Zajda, Jos Bloemers, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W. Duda, Mark Vanderkelen, M. Isabel Leite
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and disease burdens, with a need for more effective and well-tolerated treatments. Objectives: To evaluate the long-term safety, tolera
Externí odkaz:
https://doaj.org/article/5317ded6473646318a630c95493a4cc4
Autor:
James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study Group
Publikováno v:
Frontiers in Neurology, Vol 14 (2024)
ObjectiveADAPT+ assessed the long-term safety, tolerability, and efficacy of efgartigimod in adult participants with generalized myasthenia gravis (gMG).MethodsADAPT+ was an open-label, single-arm, multicenter, up to 3-year extension of the pivotal p
Externí odkaz:
https://doaj.org/article/1a89a0788ce640369ff168f37dc4e637
Autor:
Tuan Vu, Andreas Meisel, Renato Mantegazza, Djillali Annane, Masahisa Katsuno, Rasha Aguzzi, Ahmed Enayetallah, Kathleen N. Beasley, Nishi Rampal, James F. Howard
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1435-1438 (2023)
Abstract This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in t
Externí odkaz:
https://doaj.org/article/0d5bc2b774ee49aeaaee00849c3e3146
Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
Autor:
Gianvito Masi, Minh C. Pham, Tabitha Karatz, Sangwook Oh, Aimee S. Payne, Richard J. Nowak, James F. Howard Jr, Jeffrey T. Guptill, Vern C. Juel, Kevin C. O'Connor
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 5, Pp 825-831 (2023)
Abstract To compare the immunopathology of immune checkpoint inhibitor‐induced myasthenia gravis (ICI‐MG) and idiopathic MG, we profiled the respective AChR autoantibody pathogenic properties. Of three ICI‐MG patients with AChR autoantibodies,
Externí odkaz:
https://doaj.org/article/333e8afb234e4c66864662b4acd82a55
Autor:
Nedra Whitehead, Stephen W. Erickson, Bo Cai, Suzanne McDermott, Holly Peay, James F. Howard, Lijing Ouyang, the Muscular Dystrophy Surveillance, Tracking and Research Network
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-10 (2023)
Abstract Background Direct estimates of rare disease prevalence from public health surveillance may only be available in a few catchment areas. Understanding variation among observed prevalence can inform estimates of prevalence in other locations. T
Externí odkaz:
https://doaj.org/article/7c9f1424e2084e0f8508444cb1bd769f
Autor:
Tom Hughes, James F. Howard, Nicholas J. Silvestri, Ashley E. L. Anderson, Mai Sato, Sharon Suchotliff, Jeffrey T. Guptill, Glenn Phillips
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
ObjectiveBetter understanding the impact of social determinants of health (SDOH) barriers from the patient perspective is crucial to improve holistic patient support in generalized myasthenia gravis (gMG), a rare autoimmune disorder with high disease
Externí odkaz:
https://doaj.org/article/51f59b6047f2497aaf929f6cd15483ea
Autor:
James F. Howard Jr, Chafic Karam, Marcus Yountz, Fanny L. O’Brien, Tahseen Mozaffar, for the REGAIN Study Group
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 7, Pp 1398-1407 (2021)
Abstract Objective Generalized myasthenia gravis (gMG) is an autoimmune disease that causes disabling weakness via damage to the neuromuscular junction. In most patients, the disease is mediated by autoantibodies to the acetylcholine receptor, which
Externí odkaz:
https://doaj.org/article/b859aad162d34dccb7c5e73f7e6c2f00
Autor:
Shruti M. Raja, James F. Howard Jr, Vern C. Juel, Janice M. Massey, Manisha Chopra, Jeffrey T. Guptill
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 6, Iss 10, Pp 2114-2119 (2019)
Abstract Our objective is to report longitudinal results of the MG‐ADL, MG‐Composite, MG‐MMT, and MG‐QoL15 in an open‐label trial of therapeutic plasma exchange in myasthenia gravis. Ten MG patients experiencing exacerbation had assessments
Externí odkaz:
https://doaj.org/article/5c740bacb9eb44f1a034b620454eca5c
Autor:
Richard J. Nowak, Srikanth Muppidi, Said R. Beydoun, Fanny L. O'Brien, Marcus Yountz, James F. Howard
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Introduction: Chronic, broad-spectrum immunosuppressive therapy (IST) can be associated with side effects in many people with generalized myasthenia gravis (gMG), and treatment guidelines recommend that the IST dose be tapered once patients achieve a
Externí odkaz:
https://doaj.org/article/c2c624d8ca5145e090511024f093e78e